COMP <GO>
IQV vs MEDP // 10Y YIELD & FRED MACRO BETA
IQVIA Holdings Inc. (NYSE) VS. Medpace Holdings Inc. (NASDAQ) • 15-METRIC TALLY: IQV 5
— MEDP 7
▲ 10Y YIELD & FRED MACRO BETA LEADER: IQV
LAST: $258.44 (-3.32%) • MKT CAP: $44.06B
macro-sensitivity
1.16
LAST: $648.14 (-0.59%) • MKT CAP: $18.24B
macro-sensitivity
1.00
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IQV VS. MEDP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IQV | MEDP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.40% | 27.90% | -18.50 | MEDP | /roic <GO> |
| EV/EBITDA & P/E Valuation | 20.4x | 34.0x | -13.60 | IQV | /valuation <GO> |
| Free Cash Flow Yield | 4.24% | 3.60% | +0.64 | IQV | /fcf-yield <GO> |
| Operating Margin | 13.40% | 21.10% | -7.70 | MEDP | /operating-margins <GO> |
| Net Profit Margin | 8.30% | 17.80% | -9.50 | MEDP | /net-margins <GO> |
| Revenue Growth (YoY) | 5.90% | 20.00% | -14.10 | MEDP | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.22 | 9.13 | -6.91 | MEDP | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | MEDP | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.3 | 52.4 | -4.10 | MEDP | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.16 | 1.00 | +0.16 | IQV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 31.0x | 35.3x | -4.30 | IQV | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $44.06B | $18.24B | $25.82B | IQV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IQV REV | MEDP REV | IQV GROSS % | MEDP GROSS % | IQV FCF | MEDP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $16.31B | $2.53B | — | — | $1.92B | $681.9M |
| FY 2024 | $15.40B | $2.11B | — | — | $2.02B | $572.3M |
| FY 2023 | $14.98B | $1.89B | — | — | $1.47B | $348.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IQV // BETA 1.16
MEDP // BETA 1.00